I 
118TH CONGRESS 
2D SESSION 
H. R. 9785 
To require the Director of the Office of Management and Budget to submit 
to Congress an annual report on biomedical research funded by the 
United States and performed in China. 
IN THE HOUSE OF REPRESENTATIVES 
SEPTEMBER 24, 2024 
Mr. LANGWORTHY (for himself, Mr. HIGGINS of Louisiana, and Mr. DAVIS of 
North Carolina) introduced the following bill; which was referred to the 
Committee on Energy and Commerce, and in addition to the Committee 
on Agriculture, for a period to be subsequently determined by the Speak-
er, in each case for consideration of such provisions as fall within the ju-
risdiction of the committee concerned 
A BILL 
To require the Director of the Office of Management and 
Budget to submit to Congress an annual report on bio-
medical research funded by the United States and per-
formed in China. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Chinese Laboratory 
Accountability and Watchful Spending Act of 2024’’ or 
the ‘‘CLAWS Act of 2024’’. 
VerDate Sep 11 2014 
18:52 Oct 08, 2024
Jkt 059200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H9785.IH
H9785
ssavage on LAPJG3WLY3PROD with BILLS
SEC. 2. ANNUAL REPORT ON FEDERALLY-FUNDED BIO-
MEDICAL RESEARCH IN CHINA. 
(a) DEFINITIONS.—In this section: 
(1) COVERED
AGENCY.—The term ‘‘covered 
agency’’ means— 
(A) an Executive agency, as defined in sec-
tion 105 of title 5, United States Code; and 
(B) an independent regulatory agency, as 
defined in section 3502 of title 44, United 
States Code. 
(2) COVERED
PROJECT.—The term ‘‘covered 
project’’ means a project— 
(A) funded by a covered agency; and 
(B) that is awarded directly or indirectly 
through a grant, contract, other transaction 
agreement, subaward, cooperative agreement, or 
any other form of assistance to an entity that— 
(i) is located in China; or 
(ii) performs the project in whole or 
in part in China. 
(3) PROJECT.—The term ‘‘project’’ means bio-
medical research or experimentation conducted for 
the identification, control, treatment, and prevention 
of human or animal diseases, including the testing 
of any drug, biological product, device, vaccine, vac-
cine adjuvant, antiviral, or diagnostic test. 
VerDate Sep 11 2014 
18:52 Oct 08, 2024
Jkt 059200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H9785.IH
H9785
ssavage on LAPJG3WLY3PROD with BILLS
(b) REQUIREMENT.—Not later than 1 year after the 
date of enactment of this Act, the Director of the Office 
of Management and Budget shall issue guidance requiring 
covered agencies to annually include in a report described 
in paragraph (2) of section 3516(a) of title 31, United 
States Code, or a consolidated report described in para-
graph (1) of such section, information relating to each cov-
ered project of the covered agency, which shall include a 
detailed description of the covered project, including— 
(1) the purpose of the covered project; 
(2) whether the covered project involves— 
(A) pathogens with pandemic potential; 
(B) biological select agents and toxins; 
(C) dual use research of concern; 
(D) human or animal subjects; and 
(E) classified research; 
(3) each location where the covered project is 
carried out and, if applicable— 
(A) whether the research location is sub-
ject to the jurisdiction, direction, control, or op-
erates on behalf of the Government of the Peo-
ple’s Republic of China; and 
(B) whether the research location engages 
in joint research with, or is supported by, or af-
VerDate Sep 11 2014 
18:52 Oct 08, 2024
Jkt 059200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H9785.IH
H9785
ssavage on LAPJG3WLY3PROD with BILLS
filiated with China’s military, internal security 
forces, or intelligence agencies; 
(4) if applicable, the rationale for conducting 
the covered project in China; 
(5) the contract or award number of the cov-
ered project; 
(6) each covered agency or subagency funding 
the covered project; 
(7) each primary contractor, subcontractor, 
grant recipient, and subgrant recipient of the cov-
ered project; 
(8) the start date of the covered project; 
(9) the current expected date for completion of 
the covered project; 
(10) the cost of the covered project during the 
previous fiscal year; 
(11) the total cost of the covered project since 
inception; 
(12) a description of specific steps taken to en-
sure research security of the covered project; and 
(13) any noncompliance with respect to the cov-
ered project documented by the covered agency dur-
ing the reporting period. 
Æ 
VerDate Sep 11 2014 
18:52 Oct 08, 2024
Jkt 059200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6301
E:\BILLS\H9785.IH
H9785
ssavage on LAPJG3WLY3PROD with BILLS